Skip to content
The Policy VaultThe Policy Vault

Imkeldi — CareFirst (Caremark)

Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)

Initial criteria

  • Authorization of 12 months may be granted when disease is associated with PDGFR gene rearrangements

Reauthorization criteria

  • Continued treatment may be approved for 12 months when there is no evidence of unacceptable toxicity or disease progression

Approval duration

12 months